TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Long-term Debt

Borrowings due after more than one year.

TELA Bio, Inc.NASDAQ: TELA

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt rises 47.4% from a year ago

Long-term debt stood at $56.08M at the end of Q2 FY2026, up 47.4% from a year earlier and up 0.4% from the prior quarter. Over 3 fiscal years it compounded at +11.7% a year.

Context

  • Long-term debt amounted to 93.9% of total assets at the end of Q2 FY2026, up 37.5 pp from a year earlier.
  • Long-term debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +47.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$56.08M+0.4% QoQ
Last fiscal yearDec 2025
$55.65M+35.3% YoY
Year agoJun 2025
$38.05M+47.4% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.4%——
1 year+35.3%——
3-year CAGR+11.7%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
55.65M USD
Year-over-year change
+35.3%
4-year CAGR
+15.3%

Long-term Debt vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's Jun 2026 long-term debt of $56.08M is the highest of the 9 companies compared; the peer median is $125.5K.
  • Its year-over-year change of +47.4% is the highest of 4, against a peer median of -47.1%.
  • Long-term debt amounts to 93.9% of total assets for TELA, versus a peer median of 0.2%.
TELA Competitors Peer median
Long-term Debt for TELA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TELATELA Bio, Inc.Jun 2026$56.08M +47.4%+11.7%93.9%
OTLKOutlook Therapeutics, Inc.Mar 2026$11.12M -47.1%—50.8%
SPRBSpruce Biosciences, Inc.Mar 2026$5.46M —-49.7%9.7%
MDAISpectral AI, Inc.Mar 2026$5.27M -29.8%—29.7%
EQEquillium, Inc.Mar 2026$251K —-52.1%0.4%
CUECue Biopharma, Inc.Mar 2026$0 ——0.0%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
SRTSSensus Healthcare, Inc.Mar 2026$0 ——0.0%
COEPCoeptis Therapeutics, Inc.Mar 2026$0 -100.0%+0.0%0.0%
Peer median (excluding TELA) $125.5K-47.1%-49.7%0.2%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents43.93M42.02M46.73M52.67M50.85M
Short-term Investments00000
Net Receivables4.23M6.62M9.74M10.1M10.35M
Inventory7.66M11.79M13.16M12.78M11.02M
Other Current Assets02.02M2.1M2.52M3.37M
Total Current Assets59.06M62.45M71.73M78.07M75.58M
Property, Plant & Equipment (Net)1.19M2.91M3.94M4.08M3.73M
Goodwill00000
Intangible Assets2.3M2.5M2.12M1.74M1.36M
Long-term Investments00265K2.54M250K
Tax Assets000896K0
Other Non-current Assets0000500K
Total Non-current Assets3.49M5.41M6.32M9.25M5.84M
Total Assets62.54M67.86M78.05M87.33M81.42M
Account Payables2.41M1.53M1.67M2.15M2.31M
Short-term Debt0340K565K545K0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.15M4.11M5.52M5.56M15.67M
Total Current Liabilities10.58M12.4M16.97M15.6M17.98M
Long-term Debt31.49M39.92M40.52M41.12M55.65M
Deferred Tax Liabilities000756K0
Deferred Revenue (Non-current)00000
Other Non-current Liabilities380K31K001.48M
Total Non-current Liabilities31.87M41.15M42.2M43.27M57.13M
Total Liabilities42.45M53.55M59.17M58.87M75.11M
Common Stock15K19K24K39K44K
Retained Earnings(229.93M)(274.23M)(320.89M)(358.73M)(397.56M)
Accumulated OCI(52K)150K91K90K91K
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.1M14.31M18.88M28.46M6.31M
Total Debt31.49M41.46M42.77M43.06M55.65M
Net Debt(12.44M)(563K)(3.96M)(9.61M)4.81M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.